BRIEF—Leanbio builds major new biotech facility in Spain

Spanish contract development and manufacturing organization (CDMO) Leanbio is to invest an additional $22 million in a facility currently under construction near Barcelona.

The new site will house three production lines capable of manufacturing recombinant proteins and antibodies, as well as plasmid DNA and messenger RNA.

The building is expected to be operational from 2025, and will feature three GMP-certified lines dedicated to working with mammalian cells, microbial cultures, and molecules for gene therapies.

The project, which complies with all European quality and environmental standards, has also been selected as a cutting-edge Health PERTE (Strategic Project for Economic Recovery and Transformation) initiative.